Edition:
India

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.56USD
15 Dec 2017
Change (% chg)

$0.55 (+2.89%)
Prev Close
$19.01
Open
$19.10
Day's High
$19.80
Day's Low
$18.97
Volume
428,968
Avg. Vol
246,278
52-wk High
$27.07
52-wk Low
$8.73

Latest Key Developments (Source: Significant Developments)

Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Omeros Corp ::OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS.FDA APPROVED SNDA FOR OMIDRIA UNDER PRIORITY REVIEW.  Full Article

Omeros Corp reports Q3 loss per share $0.16
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Omeros Corp :Omeros Corporation reports third quarter 2017 financial results.Q3 loss per share $0.16.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Q3 revenue $21.7 million versus i/b/e/s view $17.9 million.Omeros Corp - ‍as of sept 30, 2017, co had $86.8 million of cash & cash equivalents available for operations & $5.8 million in restricted cash​.  Full Article

OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Omeros Corp ::OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY.‍OMS721 HAS BEEN WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN IDENTIFIED​.3 OF 4 PATIENTS FOR WHOM OMS721 TREATMENT WAS DISCONTINUED EARLY EXPERIENCED DETERIORATION OF THEIR CONDITIONS AND SUBSEQUENTLY DIED​.‍PREPARING TO INITIATE OMS721 PHASE 3 CLINICAL TRIAL, PURSUING FDA'S BREAKTHROUGH THERAPY DESIGNATION, EUROPEAN MEDICINES AGENCY'S PRIME STATUS​.  Full Article

Omeros Corp amends term loan agreement
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Omeros Corp :On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​.Pursuant to amendment, co to access second, third tranches of debt financing under loan agreement for up to $25 million and $20 million.  Full Article

Omeros announces pricing of public offering of common stock
Thursday, 11 Aug 2016 

Omeros Corp : Omeros announces pricing of public offering of common stock .Pricing of a $40 million underwritten public offering of its common stock at a price to public of $11.50 per share.  Full Article

Omeros announces public offering of common stock
Thursday, 11 Aug 2016 

Omeros Corp : Omeros announces public offering of common stock . Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials .Says announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co..  Full Article

Omeros confirms late-stage development plan for OMS721 with EMA
Thursday, 28 Jul 2016 

Omeros Corp : Omeros corporation confirms oms721 phase 3 development plan with european medicines agency . Initiation of enrollment in ahus phase 3 clinical trial is planned for late this year . Omeros plans to commercialize oms721 initially for administration as a subcutaneous injection .One single-arm, open-label phase 3 pivotal trial planned to support approval in both europe and u.s..  Full Article

Omeros enters debt financing transaction for $20 mln in additional funds
Tuesday, 17 May 2016 

Omeros Corp : Entered into an amendment to its existing credit facility to provide company with an additional $20 million in unrestricted cash . Will issue warrants to lenders, exercisable for 7 years for up to 100,602 shares of common stock at an exercise price per share of $9.94 . Expects funding will occur on may 18, 2016. .Omeros announces debt financing transaction for $20 million in additional funds.  Full Article

Omeros Corporation reports Q1 loss per share $0.54
Tuesday, 10 May 2016 

Omeros Corp : Omeros corporation reports first quarter 2016 financial results . Q1 loss per share $0.54 . Q1 revenue $7.4 million versus I/B/E/S view $8.8 million . Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S ."continue to expect that we will reach cash-flow positive status later this year, fully funding our pipeline".  Full Article

Omeros Corp announces exclusive Middle East distribution agreement
Tuesday, 10 May 2016 

Omeros Corporation : Omeros Corporation announces exclusive middle east distribution agreement for omidria .Distribution agreement for sale of omidria in Saudi Arabia, UAE and other countries in Middle East with Itrom Trading Drug Store.  Full Article

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS